Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG

Minako Oshima, Philip Deitiker, Tetsuo Ashizawa, M. Zouhair Atassi

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

An animal model of myasthenia gravis (MG), termed experimental autoimmune MG (EAMG), can be induced in C57BL/6 (B6, H-2b) mice by immunization with Torpedo californica acetylcholine receptor (tAChR). We have investigated the effect of vaccination with MHC class II peptide I-Aβb62-76 on clinical EAMG and on T cell and antibody (Ab) responses against tAChR. B6 mice were vaccinated with the peptide (25 μg/mouse) four times prior to two injections with tAChR. The incidence of clinical EAMG in vaccinated mice was 14% (3 out of 22 mice) compared to 48% (17 out of 35 mice) in control non-vaccinated or PBS-immunized mice. The T cells of the vaccinated group showed lower proliferative responses to tAChR and to T-cell epitope-containing tAChR α-chain peptides than the T cells of controls. In addition, the Ab responses in the vaccinated group was also lower against tAChR and some of the B-cell epitope-containing tAChR α-chain peptides.

Original languageEnglish (US)
Pages (from-to)183-190
Number of pages8
JournalAutoimmunity
Volume35
Issue number3
DOIs
StatePublished - Jul 4 2002

Keywords

  • Acetylcholine receptor
  • Immunosuppression
  • MHC
  • Myasthenia gravis
  • T cell

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG'. Together they form a unique fingerprint.

Cite this